Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. Germline SDHx mutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro-intestinal stromal tumors. The SDHx genes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dysfunction and cancer. Accumulation of succinate is the hallmark of tumorigenesis in PGL and PCC. Succinate accumulation inhibits several α-ketoglutarate dioxygenases, thereby inducing the pseudohypoxia pathway and causing epigenetic changes. Moreover, SDH loss as a consequence of SDHx mutations can lead to reprogramming of cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and other metabolites can be measured in tumor tissue, plasma and urine with different techniques. Furthermore, these pathophysiological characteristics provide insight into therapeutic targets for metastatic disease. This review provides an overview of the pathophysiology and clinical implications of oncometabolite succinate in SDHx mutations. K E Y W O R D S oncometabolites, paraganglioma, pheochromocytoma, SDH mutation, succinate 1 | INTRODUCTION Mutations of genes encoding for the succinate dehydrogenase (SDH) complex, associated with familial paraganglioma (PGL) and pheochromocytoma (PCC), lead to accumulation of succinate, which disturbs the metabolic regulation of the cell. Nowadays metabolic dysregulation is recognized as one of the eight hallmarks of cancer. 1 Although germline mutations in SDHx genes are predominantly linked to PGL and PCC, these mutations also predispose to renal cell carcinoma (RCC), gastrointestinal stromal tumors (GISTs) and, possibly, pituitary adenomas. PCC, PGL and head and neck PGL (HNPGL) are rare neuroendocrine tumors arising from chromaffin cells that can synthesize and release catecholamines. Sympathetic PGLs are derived from sympathetic paraganglia in the chest, abdomen or pelvis. PCC are PGLs located in the adrenal medulla. 2 HNPGLs are derived from parasympathetic paraganglia. Common locations for HNPGLs include the carotid body and the middle ear, as well as the vagus nerve and internal jugular vein. While parasympathetic PGLs are most often non-functional tumors, PCC and sympathetic PGL release catecholamines into the circulation and can
lead to severe (lethal) cardiovascular and cerebrovascular complications. Approximately, 40% of these tumors carry a germline mutation in one of more than 20 susceptibility genes, of which the SDHx genes are the most prevalent. 3 In terms of genomic features, tumors related to SDHx mutations are classified as cluster I, along with Von Hippel Lindau (VHL), fumarate hydratase (FH), malate dehydrogenase 2 (MDH2), hypoxia induced factor (HIF2α) and isocitrate dehydrogenase (IDH)-mutations and the recently identified SLC25A11. 4 Cluster I germline mutations predispose to tumors characterized by a pseudohypoxic signature, in contrast to cluster II germline mutations, which are associated with abnormal kinase signaling pathways and include mutations in the genes of rearranged during transfection (RET), neurofibromatosis (NF1), transmembrane protein 127 (TMEM127), kinesin family member 1B (KIF1B), and MYC-associated factor X (MAX). Cluster III is associated with the Wnt-signaling pathway; it includes somatic mutations of cold shock domain-containing E1 (CSDE1) and mastermind-like transcriptional coactivator 3 (MAML3) fusion genes. 5, 6 SDHx genes were the first to be recognized as tumor suppressor genes encoding a mitochondrial enzyme. This resulted in an upsurge of interest in the concept of aerobic glycolysis or the "Warburg effect," reported by Otto Warburg in 1926, which is characterized by high glucose consumption and lactate production of cancer cells, even in the presence of oxygen. 7 This metabolic dysregulation is in fact rec- These oncometabolites modulate the activity of α-ketoglutaratedependent dioxygenases, which are involved in the induction of the pseudohypoxia pathway and inhibit histones and DNA demethylases, resulting in a hypermethylator phenotype (also known as CpG island methylator phenotype [CIMP] ). The SLC25A11 gene encodes for a mitochondrial carrier protein that is part of the malate-asparate shuttle (this shuttle regenerates NADH to allow complex I to function), mediating the transport of α-ketoglutarate from the mitochondrial matrix to the cytoplasm in exchange with malate. Preliminary results show that in SLC25A11-mutated cells aspartate and glutamate concentration is increased inducing the pseudohypoxic pathway and hypermethylation. 4 Recognition of these pathophysiological characteristics provides unique opportunities for diagnostic and therapeutic strategies. Over the past years, several excellent reviews, such as those by Kucklova of SDHx-related tumors. [8] [9] [10] In the current review, we first present a short summary of the SDH protein and the clinical features of SDHxmutation carriers. We then focus on the oncometabolite succinate and its pivotal role in tumorigenesis in SDHx-related tumors, as well as on the implications for clinical practice, especially diagnostics and therapeutic options related to metastatic disease.
| SUCCINATE DEHYDROGENASE
SDH is a hetero-tetrameric mitochondrial enzyme that plays a role in the TCA cycle and in the mitochondrial electron transport chain as complex II (Figure 1 ). SDH catalyzes the oxidation of succinate to fumarate in the TCA cycle and transfers electrons to the ubiquinone (coenzyme Q) pool in the respiratory chain. SDH subunit A (SDHA) and subunit B (SDHB) comprise the catalytic subunits in the hydrophilic head that protrudes into the mitochondrial matrix. SDH subunit C (SDHC) and subunit D (SDHD) are the ubiquinone-binding and membrane-anchoring subunits. SDH assembly factor (SDHAF) is required for the flavination of SDHA, which is essential for the formation of the SDH complex. The SDHA gene is located on chromosome 5p15.33 and contains 16 exons. 11 SDHA is the major catalytic subunit, converting succinate to fumarate. It contains the binding site for succinate. The gene encoding for SDHB is located on chromosome 1p35-36.1 and has eight exons 12 ; the SDHB protein contains three Fe-S centers and mediates electron transfer to the ubiquinone pool.
The gene encoding SDHC is located at 1q21 and has six exons, 13 and the SDHD gene is located on chromosome 11q23 and has four exons. 14 SDHC and SDHD bind ubiquinone, generating protons eventually leading to the production of ATP.
| PHENOTYPE OF SDHX MUTATION CARRIERS
Although different SDHx mutations occur in genes encoding for a single enzyme, the clinical picture for each subunit differs with regard to penetrance, manifestations and rate of malignancy. International guidelines advice to screen all germline mutation carriers, however with different screenings strategies for different SDHx mutation carriers. 15 Screenings advices do not only differ between the different mutations, but also over time, because studies on penetrance differ over time regarding the population studied (index included or not), the imaging methods used and the duration of follow-up. Adherence to screening, leads to the detection of smaller PCC/PGL and might even lead to an improved survival for patients who develop metastases, although this is based on only few patients. 16 Until now, a clear explanation for the difference of the clinical picture between different SDHx mutations is lacking, except for the hypothesis that the extent of SDH deficiency or loss depends on the subunit. Apart from the differences, all SDHx mutations are characterized by the (potential) presence of PGL/PCC. SDHx-associated tumors harbor germline and somatic mutations, consistent with Knudson's second-hit hypothesis. 12 This hypothesis states that the combination of an inactivating germline mutation as a first hit, and somatic loss of function of the wild type allele as a second hit, is essential for tumor development. 17 This second hit usually is an inactivation of the normal allele, that is, loss of 1p as was shown in a large genomic study. 18 Germline SDHx mutations have been associated with neoplasms other than PGL/ PCC, such as RCC, [19] [20] [21] GISTs and possibly pituitary adenoma. [22] [23] [24] In addition, somatic SDHx mutations have been described in T-cell leukemia. 25 Because the discovery of SDHx genes is relatively recent, the full clinical phenotype of these carriers remains to be sufficiently clarified. The following paragraphs describe the currently known phenotype of each SDHx subunit ( Table 1 ). The question of why SDHx mutations predispose to tumors in a select subset of tissues remains elusive.
| SDHA mutations
Mutations in the SDHA gene were originally described as a cause of autosomal recessive juvenile encephalopathy, also known as Leigh syndrome. 26 Later on, in 2010, a 32 year old woman with an abdominal PGL was reported to have a heterozygous SDHA germline mutation. 27 Mutations in the SDHA gene remain a rare cause of PGL and F I G U R E 1 Succinate dehydrogenase (SDH) complex (simplified). The catalytic subunits SDH subunit A contains the flavin cofactor (FAD) which accepts electrons from succinate and passes them to Fe-S center in the SDH subunit B subunit. The electrons are then passed the ubiquinone pool embedded in SDHC and SDHD subunits. Reduced Q (QH2 = ubiquinol) transfers electrons within the mitochondrial inner membrane space to complex III account for 1% to 7% of all PGL cases. 28, 29 Metastatic disease was reported in 0% to 33% of PGL patients with SDHA mutations, although these reports included few patients (n = 4-34). [31] [32] [33] [34] [35] [36] GISTs and pituitary adenomas were reported in a small subset of patients. 24, 31, 32, 37, 38 In a large pediatric GIST study of Boikos et al, a SDHA mutation, germline or somatic, was the most common molecular subtype 39 Neuroblastoma was reported in one SDHA mutation carrier where it was possible to confirm loss of heterozygosity (LoH) in tumor tissue. 38 
| SDHB mutations
Mutations in the SDHB gene are those most frequently found in PGL and account for about 10% of all cases of PGL. 28 Most common manifestations are sympathetic PGLs (50%), whereas PCC and HNPGL occur less often (20%-25% and 20%-30%, respectively). 15 Bilateral PCCs appear to be rare in SDHB mutation carriers. Penetrance of dif- Kaplan-Meier analysis showed an estimated risk for the combined manifestation of PCC, sympathetic PGL and HNPGL in non-index patients to be 22% at age 60. 40 In their retrospective cohort analysis (index and non-index patients) the penetrance was 24% at age 60 years. 40 Males seem to be slightly more at risk than females of developing a PGL. 40, 41 SDHB-related PGL/PCC are associated with a high risk of metastasis and poor prognosis. Earlier studies report a higher metastatic rate (31%-97%) [42] [43] [44] [45] than more recent studies. 40 In a meta-analysis including 12 studies comprising both asymptomatic SDHB carriers and carriers with manifest non-metastatic disease, van Hulsteijn et al reported a metastatic rate of 17%. 46 The risk of metastasis in HNPGL in SDHB mutation carriers appears to be lower compared to PGL developing at other sites. 15 In a recent meta-analysis of the outcomes of metastatic PGL and PCC, Hamidi et al found that the overall mortality in SDHB mutation carriers ranged from 35% to 55% (n = 96) compared to an overall mortality of 53% (95% confidence interval 43%-63%) in the whole group of PGL/PCC. 47 In the past, several studies have shown an association between SDHB-related metastatic PGL/PCC and a shorter survival in patients compared to sporadic metastatic PGL/PCC. 48, 49 In a recent analysis of Hescot et al, not the SDHB mutation status but hypersecretion of metanephrines and chromogranin A was found to be a significant prognostic factor for worst overall survival. 50 Other SDHB-associated tumors include RCC, although the risk for this manifestation seems low, varying between 4.7% and 8%. 21, 40 GISTs are reported to occur in approximately 2% of SDHB carriers. 51 Pituitary adenoma have been reported in nine cases, but only three had proven LoH (loss of heterozygosity) and abnormal SDHB expression, thus confirming involvement of SDHB mutation. 24 Tufton et al reported a case of a SDHB mutation carrier with pituitary carcinoma. 52 
| SDHC mutations
Mutations in the SDHC gene account for 1% to 2% of PGL/PCC cases. 28 SDHC typically manifest as benign, non-functional HNPGL, although sympathetic PGL and PCC are also reported. 53, 54 Multiple HNPGL are common. 54 Penetrance for all PGL/PCC manifestations in a cohort of 43 non-index SDHC carriers was 25% at age 60. 40 Although metastatic disease seems to be rare in SDHC mutation carriers, it has in a few cases been reported. 40, [55] [56] [57] Eight RCC and multiple GISTs have been reported in SDHC carriers. 19, 58, 59 Two cases of pituitary adenoma have been described, although for LoH studies no tissue was available to prove pathogenicity. 24 
| SDHD mutations
A mutation in the SDHD gene accounts for approximately 5% to 9% of all cases of PGL/PCC. 28, 29 This gene follows an autosomal dominant inheritance, modified by maternal imprinting. The predominant clinical feature of SDHD carriers is the development of (multiple)
HNPGLs, as 85% of carriers develop tumors at this site. 51 PCC and sympathetic PGL occur less frequently in 10% to 25% and 20% to 25% of carriers, respectively. Penetrance for 160 non-index SDHD mutation carriers was 43% at age 60. 40 Metastatic risk in SDHD carriers is low and occurs in 7% to 8% of cases. 15, 60 Other associated tumors include RCC and GIST, although the lifetime risk for this manifestation is very low (<1%). 40, 61, 62 Pituitary adenomas are reported in five SDHD mutation carriers; in two of these, both macroprolactinomas, the presence of LoH was proven. 22,23
| SDHAF2 mutations
The SDHAF2 gene, like SDHD, is affected by maternal imprinting; therefore, only those carriers who inherit the mutation via the paternal line will develop the disease. Only a few cases of PGL/PCC associated with SDHAF2 mutations have been described, and these account for <1% of all cases of PGL. 29 Germline pathogenic variants in SDHAF2 have been seen only in association with HNPGLs. 31 HIFα regulates the transcription of several genes known to be involved in tumorigenesis, angiogenesis, extracellular matrix elements and energy metabolism. HIF1α and HIF2α share the target genes vascular endothelial growth factor (VEGF), glucose transporters 1 and 3 (GLUT1 and GLUT3) and hexokinase 2. HIF1α stimulates the expression of various glycolytic enzymes and HIF2α stimulates the expression of platelet-derived growth factor (PDGF) and erythropoietin (EPO). 9 Pollard et al showed the overexpression of HIF1α in SDHx tumors compared to tumors with other germline mutations, 71, 77 while others studies showed overexpression of HIF2α in SDHx related tumors compared to sporadic PGL/PCC. [78] [79] [80] The role of HIF3α in relation to tumorigenesis remains to be elucidated, although, previous studies have indicated that HIF3α may suppress the expression of genes induced by HIF1α and HIF2α (for review see Reference 81) .
Heat shock proteins (HSPs) are molecular chaperones that are important for protein assembly, folding and stability and play a central role in cell proliferation, survival and tumor progression. HSP90 is involved in the stability of HIF1α. 9 HSP90 has been shown to be overexpressed in metastatic PGL/PCC compared with benign PGL/PCC. 82 Inhibition of HSP90 leads to downregulation of HIF1α and is a potential target for therapy in metastatic PGL/PCC. 83 
| Accumulation of succinate leads to a hypermethylator phenotype
Recent studies have observed a hypermethylator phenotype in SDH deficient PGL/PCC. [84] [85] [86] Next to PHD, accumulation of succinate competitively inhibits other α-ketoglutarate-dependent dioxygenases,
including jumonji-domain histone demethylases (JmjC) and the ten- 84 The most significant epigenetically silenced genes were those encoding phenyl-ethanolamine-N-methyltransferase (PNMT) and keratine 19 (KRT19), which are involved in neuroendocrine differentiation and in epithelial-tomesenchymal transition (EMT). 84 PNMT catalyzes the conversion of norepinephrine to epinephrine.
Next to the PNMT gene, four other genes that we found to be hypermethylated, are involved in the catecholamine secretion: SULT1A1, DRD2, NPY, and SLC6A2. 84 Reduced expression of these genes leads to an immature catecholamine secretory profile with predominant excretion of norepinephrine and dopamine. In SDHB mutated tumors the level of hypermethylation seems to be significantly higher compared to other SDHx mutated tumors, and the expression of these target genes significantly lower. The authors hypothesize that SDH inactivation may be more complete in SDHB mutated tumors compared to tumors harboring a mutation in the other subunits, leading to a higher succinate accumulation and hence a stronger inhibition of α-ketoglutarate-dependent demethylation. 84 This could be an explanation for the higher metastatic risk in SDHB-related tumors.
The study of Richter et al confirmed that tumor succinate:fumarate ratios were higher in tumors of patients with SDHB mutations compared to tumors of patients with an SDHC/D mutation. 87 complex II can also produce a significant number. 91, 92 Accumulation of succinate results in an over-reduced ubiquinone pool resulting in a reverse electron transfer to complex I, where electrons escape as ROS. 93 Excessive ROS levels have been shown to stabilize HIFα and induce the pseudohypoxia pathway in SDHxmutated PGL/PCC. 94 In addition to the stabilization of HIFα, SDHx-mutation-induced increases in ROS have been shown to cause genomic instability that may contribute to tumorigenesis. 95 
| Warburg effect
As stated above, SDHx-related tumors display the Warburg effect. Lussey-Lepoutre et al showed that in SDHx-mutated tumor cells the increased synthesis of oxaloacetate is essential in order to produce aspartate (as well as to continue a truncated oxidative TCA cycle). Aspartate is an important precursor for protein and nucleotide biosynthesis for anabolic purposes. In SDH deficient cells, as compared to wild type cells, knockdown of pyruvate carboxylase results in complete ablation of proliferation. The authors also showed the use of glutamine and glutamate to provide intermediates that are lacking due to TCA disturbance. 104 
| APPLICATIONS FOR DIAGNOSTICS OF PGL/PCC

| SDH and immunohistochemistry
In the vast majority of SDHx-associated tumors, loss of SDHB protein expression can be detected by immunohistochemical staining with a high sensitivity and specificity (100% and 84%, respectively). 33, 108 SDHB immunohistochemistry can therefore discriminate between High resolution magic angle spinning (HR-MAS) nuclear magnetic resonance (NMR) spectroscopy is a new technique that can be used to analyze catecholamine and succinate levels both in vivo and ex vivo.
The HR-MAS NMR technique was used by the group of Taïeb to investigate the metabolic profile of SDHx-mutated tumor tissue and to compare this profile to the metabolic profile of apparently sporadic and VHL tumor tissue. 114 SDHx-related tumors had increased levels of succinate and significantly decreased levels of glutamate compared to apparently sporadic tumors and VHL-related tumors. 106 The same group also explored the possibility of quantification of oncometabolites in tissue when the tumor is still inside the patient, and shown in eight patients that 1 H-MRS ( 1 high magnetic resonance spectroscopy) adequately detected succinate resonance peaks in four patients with an SDHx-related tumor. 115 In addition, Lussey-
Lepoutre et al used 1 H-MRS to detect succinate levels in both mice
and patients with PGL in vivo. Five patients had a SDHx gene mutation and in these patients a succinate peak could be detected. 116 This offers unique opportunities for better characterizing these tumors at a metabolic level.
| Altered cell metabolism pathways: The use of 18 F-fluorodeoxyglucose positron emission tomography
According to Endocrine Society PGL/PCC guidelines, 18 [118] [119] [120] The sensitivity of FDG-PET for SDHx related tumors varies between 83% and 100%. 118, [121] [122] [123] Like glucose, 18 F-FDG is taken up by tumor cells mostly via GLUT.
After cell entry, 18 F-FDG is phosphorylated by hexokinase into 18 F-FDG-6-P, which, unlike glucose-6-P, cannot be further metabolized along the glycolytic pathway. Because the cell membrane is impermeable to 18 Increased levels of succinate may also play a role in the high uptake of 18 F-FDG by SHDx-related tumors. Garrigue et al showed that intratumoral injection of succinate significantly increased 18 F-FDG uptake in vivo and in vitro. 125 Moreover, laser-doppler did not show succinate induced 18 F-FDG uptake to be because of increased blood flow or increased capillary permeability. 125 
| IMPLICATIONS FOR TREATMENT OF METASTATIC PGL/PCC
The cornerstone treatment for patients with benign SDHx related PGL/PCC is surgery. 117 As described above, SDHB-mutation carriers are those especially at risk of metastatic disease. Even for patients with metastatic PGL/PCC, resection of the primary tumor seems to be associated with a better overall survival. 126 Metastases frequently occur in lymph nodes (distant and regional), bones, liver and lungs.
Until now, there is no curative therapy for patients with metastatic disease. The main focus of treatment is on controlling the secretion of catecholamines, thereby alleviating symptoms and controlling tumorrelated complaints. Systemic treatment options include radionuclide therapy using 131 I Metaiodobenzylguanidine (MIBG), peptide receptor radionuclide therapy (PRRT) and chemotherapy. As described above, insight in the pathways leading to tumor formation and potential metastatic disease in patients with SDHx mutations, may lead to a better response to existing therapies and provide us with a unique opportunity to develop novel targeted therapies.
6.1 | Targeting the pseudohypoxia pathway
| Restoration of PHD activity
Succinate competes with α-ketoglutarate in binding to PHD, thereby inhibiting PHD activity; therefore excess of α-ketoglutarate could restore PHD. 11, [127] [128] [129] Increasing levels of intracellular α-ketoglutarate have been shown to affect the levels of HIF1α in vitro. 127 As succinate and hypoxia act synergistically in inhibiting PHD activity, not only administering α-ketoglutarate but also inducing hyperoxia might restore PHD activity. 130, 131 Increasing the α-ketoglutarate levels in the cell, is challenging. In a recent mouse model study of breast cancer, the α-ketoglutarate dehydrogenase (KGDH) inhibitor (AA6) was able to cause intracellular α-ketoglutarate accumulation. 132
| HIF2α inhibition
In the HIF2α structure is a specific cavity which can be targeted. 133, 134 Pazopanib, similar to sunitinib, also inhibits the action of VEGFR, PDGFR and the RET receptor, but additionally inhibits the fibroblast growth factor receptor (FGFR). Pazopanib was studied in a phase II trial, terminated due to poor accrual after including only seven patients. 142 Six patients were evaluated, as one withdrew informed consent. Of the six only one patient had a partial response, lasting 2.4 years.
Preliminary results of axitinib were presented at the ASCO meeting in 2015. Axitinib only blocks VEGFR, and led to a partial response in three out of nine patients with metastatic PGL/PCC; moreover toxicity led to a high rate of dose reduction. 143 Cabozantinib seems a promising TKI for patients with metastatic PGL/PCC, especially for patients with bone metastases. Cabozantinib also inhibits the c-Met receptor pathways and may therefore delay the development of resistance, as this pathway is upregulated by VEGFR inhibition. Currently there is a phase II trial ongoing, with promising preliminary results. 144 Another phase II trial is aiming to evaluate the response rate of lenvatinib in a group of 25 patients with metastatic PGL/PCC. Lenvatinib, like pazopanib, also inhibits FGFR.
| Heat shock protein 90 inhibitors
Inhibition of HSP90 leads to downregulation of HIF1α and is a potential target for therapy in metastatic PGL/PCC. Giubellino et al showed potent inhibition of proliferation in PCC cell lines by tanespimycin (17-AAG) and ganetespib. Furthermore, they showed the efficacy of 17-AAG and ganetespib in reducing metastatic burden and increasing survival in a metastatic model of PCC. 83 Chae et al suggested that HSP90 could be especially effective in SDHB-mutated tumors.
Genetic inactivation of SDHB leads to a recruitment of HSP90 to the mitochondria, to help compensate for the impaired oxidative phosphorylation. As HSP90 promotes the stability of HIFα, its inhibition can lead to the death of these cells. 145 6.2 | Targeting the hypermethylator phenotype of SDHx related PGL/PCC Chemotherapy is, in contrast to therapies mentioned above, widely available for the treatment of metastatic PGL/PCC. The combination of cyclophosphamide, vincristine and dacarbazine (CVD) is the most studied and is currently first line chemotherapy in patients with a metastatic PGL/PCC. However, in the absence of prospective studies, the evidence is only based on small retrospective studies. 141, [146] [147] [148] [149] [150] [151] In 2014, a meta-analysis was performed suggesting a partial response of 37%. 152 Some reports however, suggest a higher response rate to temozolomide, an oral alternative to dacarbazine, in patients with tion. 153 Thirty-six percent had partial response, 55% stable disease and 9% progressive disease. The authors observed a longer progression-free survival in patients with an SDHB mutation compared to patients without an SDHB mutation (19.7 vs 2.9 months).
The higher response rate in patients with SDHB mutations could be caused by hypermethylation of the MGMT promotor region and consequently lower MGMT expression.
Recently two patients with a SDHB metastatic PGL/PCC showed a clinical benefit from temozolomide even after disease progression on CVD. Both patients showed hypermethylation of the MGMT promotor region, suggesting that monotherapy of temozolomide may benefit patients with metastatic SDHB-related PGL/PCC. 154 Very recently Jawed et al studied 12 patients with a metastatic PGL/PCC, all with SDHB mutation, who received CVD; a marked efficacy was noted. 155 Two out of 12 patients had a complete remission and eight patients a partial response. The median duration of response was 478 days, with a median progression-free survival of 930 days.
Decitabine, registered for the treatment of acute myeloid leukemia, is a cytidine deoxynucleoside-analog. It inhibits DNAmethyltransferase and therefore acts as a hypomethylating agent. In two cell models decitabine was able to induce cell death of SDH −/− cells. 84 
